Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
- PMID:29467649
- PMCID: PMC5808243
- DOI: 10.3389/fphar.2018.00017
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Abstract
The serotonin (5-HT) 2A receptor is the primary molecular target of serotonergic hallucinogens, which trigger large-scale perturbations of the cortex. Our understanding of how 5-HT2A activation may cause the effects of hallucinogens has been hampered by the receptor unselectivity of most of the drugs of this class. Here we used 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine), a newly developed selective 5-HT2A agonist, and tested it with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion. 25CN-NBOH evoked HTRs with an inverted u-shape-like dose-response curve and highest efficacy at 1.5 mg/kg, i.p. HTR occurrence peaked within 5 min after agonist injection, and exponentially decreased to half-maximal frequency at ~11 min. Thorough habituation to the experimental procedures (including handling, saline injection, and exposure to the observational boxes 1 day before the experiment) facilitated the animals' response to 25CN-NBOH. 25CN-NBOH (1.5 mg/kg, i.p.) induced HTRs were blocked by the 5-HT2A antagonist ketanserin (0.75 mg/kg, 30 min pre), but not by the 5-HT2C antagonist SB-242084 (0.5 mg/kg, i.p., 30 min pre). SB-242084 instead slightly increased the number of HTRs occurring at a 3.0-mg/kg dose of the agonist. Apart from HTR induction, 25CN-NBOH also modestly increased locomotor activity of the mice. Repeated once-per-day injections (1.5 mg/kg, i.p.) led to reduced occurrence of 25CN-NBOH induced HTRs. This intermediate tolerance was augmented when a second (higher) dose of the drug (3.0 mg/kg) was interspersed. Short-interval tolerance (i.e., tachyphylaxis) was observed when the drug was injected twice at intervals of 1.0 and 1.5 h at either dose tested (1.5 mg/kg and 0.75 mg/kg, respectively). Inducing ketanserin-sensitive HTRs, which are dependent on environmental valences and which show signs of tachyphylaxis and tolerance, 25CN-NBOH shares striking features common to serotonergic hallucinogens. Given its distinctin vitro selectivity for 5-HT2A over non5-HT2 receptors and its behavioral dynamics, 25CN-NBOH appears to be a powerful tool for dissection of receptor-specific cortical circuit dynamics, including 5-HT2A related psychoactivity.
Keywords: 25CN-NBOH; 5-HT2A receptor; 5-HT2C receptor; head twitch response; locomotion; serotonergic hallucinogen; tachyphylaxis; tolerance.
Figures





Similar articles
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.Halberstadt AL, van der Zee JVF, Chatha M, Geyer MA, Powell SB.Halberstadt AL, et al.Psychopharmacology (Berl). 2019 Feb;236(2):821-830. doi: 10.1007/s00213-018-5118-y. Epub 2018 Nov 17.Psychopharmacology (Berl). 2019.PMID:30448990Free PMC article.
- Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL.Fantegrossi WE, et al.Psychopharmacology (Berl). 2015 Mar;232(6):1039-47. doi: 10.1007/s00213-014-3739-3. Epub 2014 Sep 17.Psychopharmacology (Berl). 2015.PMID:25224567Free PMC article.
- Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties ofN-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist.Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Bräuner-Osborne H, Kehler J, Kristensen JL.Jensen AA, et al.J Pharmacol Exp Ther. 2017 Jun;361(3):441-453. doi: 10.1124/jpet.117.239905. Epub 2017 Mar 30.J Pharmacol Exp Ther. 2017.PMID:28360333
- 25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor.Märcher Rørsted E, Jensen AA, Kristensen JL.Märcher Rørsted E, et al.ChemMedChem. 2021 Nov 5;16(21):3263-3270. doi: 10.1002/cmdc.202100395. Epub 2021 Aug 21.ChemMedChem. 2021.PMID:34288515Review.
- Effect of Hallucinogens on Unconditioned Behavior.Halberstadt AL, Geyer MA.Halberstadt AL, et al.Curr Top Behav Neurosci. 2018;36:159-199. doi: 10.1007/7854_2016_466.Curr Top Behav Neurosci. 2018.PMID:28224459Free PMC article.Review.
Cited by
- Cellular rules underlying psychedelic control of prefrontal pyramidal neurons.Ekins TG, Brooks I, Kailasa S, Rybicki-Kler C, Jedrasiak-Cape I, Donoho E, Mashour GA, Rech J, Ahmed OJ.Ekins TG, et al.bioRxiv [Preprint]. 2023 Oct 23:2023.10.20.563334. doi: 10.1101/2023.10.20.563334.bioRxiv. 2023.PMID:37961554Free PMC article.Preprint.
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.Halberstadt AL, van der Zee JVF, Chatha M, Geyer MA, Powell SB.Halberstadt AL, et al.Psychopharmacology (Berl). 2019 Feb;236(2):821-830. doi: 10.1007/s00213-018-5118-y. Epub 2018 Nov 17.Psychopharmacology (Berl). 2019.PMID:30448990Free PMC article.
- Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task.Elsilä LV, Korhonen N, Hyytiä P, Korpi ER.Elsilä LV, et al.Front Pharmacol. 2020 Dec 3;11:602770. doi: 10.3389/fphar.2020.602770. eCollection 2020.Front Pharmacol. 2020.PMID:33343373Free PMC article.
- The serotonin 2A receptor agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner.Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T.Buchborn T, et al.J Psychopharmacol. 2020 Jul;34(7):786-794. doi: 10.1177/0269881120903465. Epub 2020 Feb 12.J Psychopharmacol. 2020.PMID:32048564Free PMC article.
- The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents.Kim YJ, Kook WA, Ma SX, Lee BR, Ko YH, Kim SK, Lee Y, Lee JG, Lee S, Kim KM, Lee SY, Jang CG.Kim YJ, et al.Arch Pharm Res. 2024 Apr;47(4):360-376. doi: 10.1007/s12272-024-01491-4. Epub 2024 Mar 29.Arch Pharm Res. 2024.PMID:38551761
References
- Buchborn T., Grecksch G., Dieterich D. C., Höllt V. (2016). Tolerance to lysergic acid diethylamide: overview, correlates, and clinical implications, in Neuropathology of Drug Addictions and Substance Misuse, ed Preedy V. R. (San Diego, CA: Academic Press; ), 846–858.
LinkOut - more resources
Full Text Sources
Other Literature Sources